Study title:
A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors
Long title:
A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors
Date receipt dossier:
11 oct 2019
EU record number:
ADP-0055-001
EudraCT number:
2019-001965-34
Pharmaceutical study code:
A2M4CD8
Company / Sponsor:
Adaptimmune LLC
Phase:
I
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
MAGE-A4 positive tumors
Therapeutic approach:
Immunotherapy
Genetic modification:
MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor
Method of transfer of nucleic acid of interest:
Lentiviral vectors
Administered biological material:
Autologous T cells transduced with lentiviral vectors expressing a MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor.
Route of administration:
Intravenous
Locations in Belgium:
Cliniques Universitaires Saint-Luc; UZ Antwerpen; U Gent
Type of procedure:
Contained use only
Current status:
Authorized